Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/ neu-positive tumour cells.
Saved in:
| Title: | Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/ neu-positive tumour cells. |
|---|---|
| Authors: | Karagiannis, Panagiotis1, Singer, Josef2, Hunt, James3, Gan, Samuel K. E.3, Rudman, Sarah M.4, Mechtcheriakova, Diana2, Knittelfelder, Regina2, Daniels, Tracy R.5, Hobson, Philip S.3, Beavil, Andrew J.3, Spicer, James4, Nestle, Frank O.1, Penichet, Manuel L.5,6,7, Gould, Hannah J.3, Jensen-Jarolim, Erika2, Karagiannis, Sophia N.1,2 sophia.karagiannis@kcl.ac.uk |
| Source: | Cancer Immunology, Immunotherapy. Jun2009, Vol. 58 Issue 6, p915-930. 16p. 1 Diagram, 4 Charts, 5 Graphs. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
